

The microbiology of asthma

Michael R. Edwards^{1,2} Nathan W. Bartlett¹ Tracy Hussell¹ Peter Openshaw¹ and Sebastian L. Johnston¹

Abstract | Asthma remains an important human disease that is responsible for substantial worldwide morbidity and mortality. The causes of asthma are multifactorial and include a complex mix of environmental, immunological and host genetic factors. In addition, epidemiological studies show strong associations between asthma and infection with respiratory pathogens, including common respiratory viruses such as rhinoviruses, human respiratory syncytial virus, adenoviruses, coronaviruses and influenza viruses, as well as bacteria (including atypical bacteria) and fungi. In this Review, we describe the many roles of microorganisms in the risk of developing asthma and in the pathogenesis of and protection against the disease, and we discuss the mechanisms by which infections affect the severity and prevalence of asthma.

Asthma exacerbations
Worsening or increased
severity of asthma symptoms.

Asthma is a chronic airway disease for which the symptoms are wheezing, breathlessness, chest tightness and coughing, with variable and often reversible airway obstruction accompanied by airway hyper-reactivity. These symptoms result from a range of processes, including contraction of airway smooth muscle (ASM), airway inflammation, airway infections, immunoglobulin E-mediated allergic responses, exposure to pollutants, exercise, stress and the stimulation of cholinergic and sensory nerves¹. A key feature of asthma is decreased lung function, measured as a reduction in either the peak expiratory flow (PEF) or the forced expiratory volume in 1 second (FEV₁). Some of the immediate symptoms of asthma are reversed by a short-acting inhaled β_2 agonist, but longer-term control requires inhaled anti-inflammatory glucocorticoids.

Worldwide, asthma affects ~300 million people, including both adults and children. It is associated with onset early in life and is increasing in incidence in the developed world. An interesting aspect of asthma is its heterogeneous, complex nature and the fact that it can present as a chronic, stable disease and as asthma exacerbations. Asthma can be severe or mild, and can vary spontaneously in activity and greatly in terms of the time of onset or the response to therapy. Indeed, whether asthma is one disease or a spectrum of related but subtly different conditions is often debated², and asthma has recently been divided into separate phenotypes, which are in turn subdivided into several endotypes³ (TABLE 1). Asthma exacerbations are often triggered by multiple factors that may work in an additive or synergistic manner. This complex pathogenesis

has made it challenging to understand the cellular mechanisms that are responsible for asthma, to decipher candidate genetic predispositions and to identify causative agents. The causes of asthma are multifactorial, and epidemiological studies spanning three decades across five continents have proved that there is a strong association between respiratory infections and the risk and pathogenesis of asthma.

In this Review, we summarize the association of microorganisms with asthma, discuss the importance of such organisms for the disease and consider the idea that part of the cause and at least some of the pathogenesis of asthma — in particular, of asthma exacerbations — result from microorganisms and their components. We also discuss the potential therapeutic value of microorganisms and their products for treating asthma and argue that future treatment and management of the disease must carefully consider the role of microorganisms.

Microorganisms and asthma onset

The hygiene hypothesis. The hygiene hypothesis posits that repeated exposure to diverse common infections (in particular, with bacteria, food-borne and orofaecal parasites⁴, and hookworms⁵) and exposure to environmental microbiota during childhood^{6,7} are strongly associated with a healthy maturation of the immune system and with protection from the development of asthma and allergies later in life^{8,9}. Our understanding of the importance of microorganisms in protection from allergies and asthma has been recently enhanced by a molecular analysis of the microbiome. Populations that live in environments with diverse microbiological

¹National Heart and Lung Institute, Centre for Respiratory Infection and MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London.

²Wright Fleming Institute of Infection and Immunity, Imperial College London, Norfolk Place, London W2 1PG, UK.

Correspondence to M.R.E.
e-mail: michael.edwards@imperial.ac.uk

doi:10.1038/nrmicro2801
Published online 6 June 2012

Table 1 | **Asthma phenotypes**

Asthma phenotype	Description
Atopic (allergic) asthma	<ul style="list-style-type: none"> • Reactivity to one or more known allergens (determined by skin prick test) • Higher than normal IgE levels • Specific IgE to allergen (determined by radioallergosorbent assay*) • Eosinophils in the airways (common but not always)
Non-allergic asthma	<ul style="list-style-type: none"> • No known allergy • No or low serum IgE • No reactivity to allergen (determined by skin prick test or radioallergosorbent assay*)
Mild asthma	<ul style="list-style-type: none"> • Occasional symptoms, but well controlled by therapy (low-dose glucocorticoids and/or short-acting β_2 agonists)
Stable asthma	<ul style="list-style-type: none"> • Well-controlled symptoms • No dysregulated lung function or asthma exacerbations
Severe asthma	<ul style="list-style-type: none"> • Poor control of symptoms despite using maximal therapy (high-dose glucocorticoids and/or β_2 agonists, or other therapies)
Asthma exacerbations	<ul style="list-style-type: none"> • Mild or severe asthma with sudden symptom onset, often requiring medical consultation or hospitalization and possible oral glucocorticoid intervention
Neutrophilic asthma	<ul style="list-style-type: none"> • Increased number of neutrophils in bronchoalveolar lavage or sputum samples (can be allergic or non-allergic asthma)
Allergic bronchopulmonary aspergillosis	<ul style="list-style-type: none"> • Invasive colonization of the airway with <i>Aspergillus</i> spp., an opportunistic pathogen; <i>Aspergillus</i> growth promotes allergic sensitization to at least 12 known fungal allergens
Virus-induced wheeze or bronchiolitis	<ul style="list-style-type: none"> • Common in young children (<2 years of age) • Asthma caused by a viral infection, mucus and inflammation in young children, giving a typical 'wheezy' episode • Mild, severe, acute onset or febrile
High T_H2 -associated atopic asthma	<ul style="list-style-type: none"> • T_H2 cell-associated gene expression is typical (for example, expresses <i>IL13</i> and <i>IL-13</i>-inducible genes) • Responds well to glucocorticoids • Prone to asthma exacerbations¹³⁵
Low T_H2 -associated atopic asthma	<ul style="list-style-type: none"> • A mixed phenotype of asthma • Less prominent T_H2 type cytokine responses • More refractory to glucocorticoid treatment than patients with high T_H2-associated atopic asthma¹³⁵

IgE, immunoglobulin E; T_H2 , T helper 2. *A radioallergosorbent assay is a blood test that is used to quantify allergen-specific IgE antibodies.

flora are associated with a low incidence of asthma, whereas populations that live in environments with low microbiological diversity are associated with a higher incidence of asthma⁷. The incidence of bacteria and their components in different environments has been studied using culture-dependent and molecular methods^{10–12}, and both qualitative and quantitative differences are found between countries with a high incidence of atopy and those with a low incidence of atopy¹⁰. Evidence for the hygiene hypothesis is also supported by experiments in mice, whereby intranasal exposure to *Escherichia coli*¹³ or *Acinetobacter lwoffii* str. F78 protects against allergic inflammation of the airways¹⁴. In addition, a link has been established between the fermentation of dietary fibre by the mouse intestinal microbiota and protection against inflammatory diseases, including asthma¹⁵. Although these studies provide experimental support for the hygiene hypothesis, our understanding of the mechanistic basis of this phenomenon is still in its infancy. These studies have also promoted the use of bacterial components such as Toll-like receptor (TLR) ligands and other pathogen-associated molecular patterns as potential therapies for asthma (TABLE 2).

Respiratory syncytial virus and rhinovirus infection in infants and bronchiolitis. Much evidence points to a relationship between severe lower respiratory infections with human respiratory syncytial virus (human RSV; referred to hereafter as RSV) or human rhinoviruses (RVs) early in life and the development of recurrent wheeze followed by asthma diagnosis in later childhood. RSV is a negative-sense single-stranded RNA (ssRNA) virus of the *Paramyxoviridae* family. It is an important pathogen of young children (<2 years of age) and accounts for ~70% of severe infantile viral bronchiolitis cases¹⁶. Serological monitoring shows that RSV infects nearly all children in their first 2 years of life; however, only ~40% of children exhibit clinical signs of infection in the lower respiratory tract. For unknown reasons, some children with bronchiolitis develop recurrent respiratory symptoms. RVs are members of the family *Picornaviridae*, are composed of a positive-sense ssRNA genome of approximately 7.1–7.5 kb and can be grouped into the major and minor groups on the basis of their host receptors: major group viruses bind intercellular adhesion molecule 1 (ICAM1), whereas minor group viruses bind low-density-lipoprotein receptor (LDLR). RVs can also be classified into three groups on the basis

Atopy
Reactivity to innocuous substances; caused by immunoglobulin E antibodies.

Wheeze
Fluid or mucus in the airways, which gives rise to a typical 'wheezy' sound when breathing.

Table 2 | **Current and future treatments for asthma**

Treatment	Notes
Glucocorticoids	<ul style="list-style-type: none"> • Anti-inflammatory small molecules that bind the cytosolic glucocorticoid receptor and both suppress inflammation and induce anti-inflammatory pathways
β_2 agonists	<ul style="list-style-type: none"> • Widely used therapies that reduce contraction of airway smooth muscle and result in bronchodilation • Can be short or long acting
Leukotriene receptor antagonists	<ul style="list-style-type: none"> • Prevent cysteinyl leukotrienes from binding the CysLT1 receptor and inducing airway smooth muscle contraction, mucus secretion and airway inflammation • For example, montelukast
Therapies against T_H2 type cytokines	<ul style="list-style-type: none"> • Monoclonal antibodies and soluble receptors against IL-4, IL-13 and IL-5 • Reduce circulating levels of T_H2 type cytokines^{136–138}
IgE-specific antibodies	<ul style="list-style-type: none"> • Monoclonal antibodies (for example, omalizumab) • Reduce levels of circulating and cell-bound IgE • A striking effect of this therapy on the incidence of asthma exacerbations has been recently reported¹³⁹
Therapies against TNF	<ul style="list-style-type: none"> • Soluble TNF receptors or TNF-specific antibodies • Reduce levels of circulating TNF (a major pro-inflammatory cytokine implicated in asthma pathogenesis) • Have shown limited efficacy in asthma treatment, and there are some safety concerns¹⁴⁰
Vitamin D	<ul style="list-style-type: none"> • A link between infection risk, asthma and vitamin D has received much attention recently^{141–143} • Data suggest an association between vitamin D and asthma risk, but a clear mechanism of how vitamin D prevents asthma is still being sought
Probiotics	<ul style="list-style-type: none"> • Probiotics with immunomodulatory potential have been applied to allergy and asthma^{144–146} as a result of the recent rise in the number of studies advocating a role for microorganisms in asthma and other inflammatory disorders
Pathogen-associated molecular pattern and TLR agonists	<ul style="list-style-type: none"> • Shown to have a good efficacy as a treatment in animal models of asthma^{147,148} • Beginning to appear in clinical trials for allergic rhinitis but have yet to be applied to asthma in humans
IFNs	<ul style="list-style-type: none"> • Human studies suggest that IFNα has a clinical benefit in stable asthma¹⁴⁹ • IFNβ is currently in a clinical trial for asthma exacerbations • IFNλs reduce allergic airway inflammation in mice¹⁵⁰

IFN, interferon; IgE, immunoglobulin E; IL, interleukin; TLR, Toll-like receptor; T_H2 , T helper 2; TNF, tumour necrosis factor.

of nucleotide sequence identity (RV-A, RV-B and RV-C). The recently proposed RV-C group viruses^{17,18} have unique sequences at the ICAM1- and LDLR-binding sites, suggesting that they use a different (but currently unknown) receptor¹⁹. It is estimated that there are more than 100 serotypes of RVs, meaning that multiple serotypes may infect an individual throughout the year²⁰. Recent cohort studies suggest that lower respiratory infections by RVs are as important as infections by RSV in terms of the risk of later asthma development^{21–23}.

Whether these viruses are true causative agents of asthma or (owing to shared risk factors) simply act as markers for an increased risk of asthma development, or even whether both possibilities are true, is unclear and much debated. RSV-mediated bronchiolitis is clearly associated with later asthma development^{24,25}, perhaps owing to an inappropriate or overexuberant immune response to the infection²⁶. Although associations between RSV, wheeze and asthma development are evident, birth cohort studies have shown that 90% of non-atopic wheezers lose this phenotype at school age and have normal lung function, indicating that asthma and virus-induced wheeze may be distinct diseases²⁷. The association of RSV with asthma is most clearly demonstrated in a long-term (18 years) study of a cohort of Swedish children. The most recent update from this

study²⁸ reports that, compared with controls, children who have RSV-mediated bronchiolitis in infancy are more likely to be asthmatic at 18 years old (39% versus 9%), show increased sensitization to perennial allergens (41% versus 14%) and have striking persistent and recurrent wheeze (30% versus 1%). Children with a history of bronchiolitis have an enhanced interleukin-4 (IL-4) (that is, T helper 2 (T_H2) type) response to RSV and cat allergens, whereas controls have an equally strong interferon- γ (IFN γ) (that is, T_H1 type) response to RSV antigens²⁹. However, it is not yet clear whether the inflammation caused by viruses causes long-term respiratory disease or is associated with wheeze and asthma diagnosis because of shared risk factors.

Animal studies have further contributed to our understanding of this phenomenon³⁰, and although many clinical studies are compatible with a direct effect of RSV on the later development of recurrent childhood wheeze, it has been hard to prove this direct causal relationship. The strongest evidence that human RSV-mediated bronchiolitis has long-term effects comes from studies of palivizumab (Synagis; MedImmune), a monoclonal antibody that prevents infection by RSV in infancy. These studies suggest a causal link between infantile RSV-mediated disease and wheeze followed by asthma diagnosis in later childhood; in a study of




Figure 1 | The microbiome is influenced by and may determine factors affecting asthma. The microbiome is regulated by diet, environmental factors (such as smoking and pollution), treatment, host genetics, and previous infections and host immunity. The diversity of the microbiome may in turn affect asthma development, as suggested by the hygiene hypothesis, and may influence the pathogenic species that contribute to stable and severe asthma and asthma exacerbations.

191 palivizumab-treated and 230 control (untreated) premature babies who were followed for 24 months, the rates of recurrent wheeze were about 50% lower in those who had prophylactic treatment with palivizumab³¹. More recently, palivizumab prophylaxis was shown to be associated with a similar substantial protection against recurrent wheeze in children aged 2–5 years³².

Much debate has focused on which of these viruses are more important to asthma development, RSV or the RVs. The answer is likely to be complicated and may involve host genetics and susceptibility factors as well as the nature of the viruses themselves. It is possible that RSV and RVs contribute to asthma development in different ways. A recent study has shown that allergic sensitization precedes or is a risk factor for symptomatic infection with RVs, and both sensitization and RV infection are strongly correlated with the occurrence of asthma at 6 years of age³³. By contrast, the role of RSV infection in this study seemed to be different, as sensitization did not increase the risk of infection in this cohort.

In the absence of independently conducted, placebo-controlled prospective studies of specific prophylaxis measures, doubt will remain about the nature of the association between infections with these viruses in infancy and the later development of childhood asthma. However, the evidence obtained so far raises hope that preventing such infections will have long-term beneficial effects on asthma development.

Specific asthma phenotypes or endotypes

Stable asthma. Microorganisms are now also thought to be important in the development and pathogenesis of stable asthma. 16S ribosomal RNA gene sequencing was carried out on bronchial brushings or bronchoalveolar lavage (BAL) from patients with stable asthma, patients with chronic obstructive pulmonary disease (COPD) and healthy controls³⁴, and revealed 5,054 bacterial sequences that were unique to the 43 subjects

with asthma or COPD, with each bronchus containing a mean of 2,000 bacterial genomes per cm² surface sampled. Pathogenic proteobacteria, particularly *Haemophilus* spp., were more frequent in the bronchi of adults with asthma or COPD than in the bronchi of controls. Similar increases in proteobacteria were found in children with asthma. In addition, there was a lack of members of the phylum Bacteroidetes in individuals with asthma when compared with controls, suggesting a potential role for commensals as well as pathogens in influencing asthma³⁴. It is thought that such commensals may stimulate the immune system such that pathogenic species are eliminated if and when infection occurs (FIG. 1). Changes in the abundance and diversity of commensals can also affect subsequent infection by influenza viruses in mice³⁵. The lower airway thus contains a characteristic microbiota that is quantitatively and qualitatively different in patients with stable asthma or COPD than in control subjects³⁴. This study challenges the previously held belief that in healthy individuals the lower airway is a sterile environment that does not support a complex microbial ecology. The diversity of bacteria that has now been revealed suggests that clinically important microorganisms which are unidentifiable by culture have roles in airway diseases such as asthma.

Invasive pneumococcal infection (IPI), which is caused by the common pathogen *Streptococcus pneumoniae*, has also been linked to asthma. Adults with stable asthma have been shown to have a greater incidence of *S. pneumoniae* carriage³⁶, and asthma has been shown to be a risk factor for IPI in both adults^{37,38} and children³⁹. One study had a particularly important finding³⁷: for low-risk asthma (as defined by the need for prescription medication for asthma) the odds ratio for IPI (versus no IPI) was 2.8-fold, whereas for high-risk asthma (as defined by hospitalization for asthma in the past 12 months) it was over 12-fold. Together, these studies show the importance of asthma in the risk of invasive *S. pneumoniae* infections, and combined with the other studies they strongly advocate the need for antipneumococcal vaccination for individuals with asthma.

Atopic (allergic) asthma. Atopic asthma is the most common form of asthma and is often characterized by eosinophils in BAL and sputum. Filamentous fungal species of the *Aspergillus*, *Alternaria*, *Cladosporium*, *Penicillium* and *Didymella* genera (in the phylum Ascomycota) produce spores that may act as allergens and initiate bronchial asthma in atopic individuals⁴⁰. Comparative genomics studies have identified proteins that act as allergens in 22 fungal species⁴¹, many of which are ubiquitous in the environment and commonly found on grains and cereals. The release and abundance of fungal spores is affected by environmental factors, including season, humidity, rainfall and temperature⁴². Many fungal aeroallergens increase in abundance in the summer along with pollen levels and have been shown to be further increased by summer storms that include lightning strikes. Indeed, fungal aeroallergens have been associated with asthma epidemics that occur during summer

Odds ratio
A measure of the ratio of the probability that an event will occur in one group versus another.

lightning strikes⁴³, possibly owing to spore aerosolization and fragmentation to produce finer particles that easily find their way to the lower respiratory tract.

Neutrophilic (non-eosinophilic) asthma. Neutrophilic asthma is a less common form of the disease that is characterized by neutrophils, with or without eosinophils, being the most abundant granulocyte in the airways of the patient⁴⁴. Respiratory viral infections have been associated with airway neutrophilia: asthmatic adults experiencing asthma exacerbations show increased airway neutrophilia⁴⁵, including neutrophil elastase in their sputum⁴⁶. Respiratory viruses can induce neutrophil chemokine synthesis and release^{45,47}, providing a mechanistic link between neutrophilic asthma and virus infections. Bacterial pathogens such as *Haemophilus influenzae*, *Staphylococcus aureus*, *Moraxella catarrhalis* and *Pseudomonas aeruginosa* have also been associated with neutrophilic asthma, with one study showing an association between airway neutrophils, increased bacterial load and the neutrophil chemokine IL-8 (also known as CXCL8)⁴⁸.

Severe or poorly controlled asthma. Recently, a molecular approach was used to investigate the microbiota in poorly controlled asthma⁴⁹, and the results suggest an association between the families Comamonadaceae, Sphingomonadaceae and Oxalobacteraceae and airway hyper-reactivity. Furthermore, this study shows that the bacteria which are found in the lung differ in health and disease and that the abundance of particular phylotypes, including members of the families Comamonadaceae, Sphingomonadaceae, Oxalobacteraceae and others, is highly correlated with the degree of bronchial hyper-responsiveness (disease severity).

Fungi have also been associated with severe asthma^{50,51}. In fact, severe asthma with fungal sensitization (SAFS) has been considered as an independent subgroup of severe asthma, and patients with SAFS may benefit from antifungal therapy. In a recent clinical trial of antifungal therapy in patients with SAFS, improvements were seen in antifungal-treated patients (versus placebo-treated patients) in terms of asthma-related quality of life, rhinitis score, lung function and total serum IgE⁵².

Allergic bronchopulmonary aspergillosis. Allergic bronchopulmonary aspergillosis (ABPA) is a unique form of asthma that is caused by colonization of the lower respiratory tract with *Aspergillus* spp. Chronic infection with *Aspergillus fumigatus* can lead to bronchiectasis⁵³, a disease that can occur in parallel with asthma and is characterized by neutrophilic inflammation, epithelial destruction and degradation of the connective tissue matrix. In this disease, the fungus acts as both a source of allergen and a pathogen, and symptoms of ABPA can be attributed to both functions. *Aspergillus* spp. are widespread fungi and potent sources of allergens⁵⁴, as shown by the reactivity of human IgE to at least 12 allergens derived from these species⁵⁵. Recently, the genome of *A. fumigatus* was sequenced⁵⁶, and nine new potential

allergens were identified on the basis of sequence identity with other known allergens. The predicted and known allergens of *A. fumigatus* are diverse in nature and include secreted proteases, glucanases and cellulases. Recent work suggests that some *A. fumigatus* allergens are 'hidden' from the immune system; hydrophobin (RodA) is an immunologically inert surface protein on dormant conidia, and removal of RodA through chemical or genetic means produces conidia that are able to activate the immune system, potentially explaining why fungal species often do not evoke immune responses in healthy individuals⁵⁷.

Colonization by *A. fumigatus* results in sensitization to fungal allergens and, subsequently, leads to allergic and/or asthma symptoms, eosinophilic and neutrophilic pneumonia⁵³, and lung damage caused by the extracellular hyphae and lung inflammation. An infection model in mice using a bioluminescent *A. fumigatus* strain⁵⁸ revealed that infection results in extensive haemorrhagic bronchopneumonia, characterized by inflammatory lesions on the bronchi and bronchioles, underscoring the potentially aggressive nature of this pathogen in affected individuals. Furthermore, *A. fumigatus* infection has been linked to IgE sensitization, airway neutrophilia and decreased lung function in ABPA, and antifungal therapy has also recently been shown to be effective in patients with ABPA⁵⁹.

Microorganisms in asthma exacerbations. Respiratory viruses are the major viruses associated with asthma exacerbations, accounting for 50–60% of exacerbations in all age groups^{60,61} (FIG. 2). RV-C may represent a group that causes more severe exacerbations, although how this occurs is unknown¹⁸. Epidemiological studies have shown that, in the northern hemisphere, infections by RVs result in a marked increase in emergency room admissions owing to asthma exacerbations. In fact, this 'asthma epidemic' has been shown to coincide with Labour Day in Canada⁶⁰, which is in the third week of September, ~2 weeks after children return to school, highlighting the important role of school-age children as vectors of virus-induced asthma exacerbations. Mouse models of infection with major and minor group RVs^{62,63} and of RV-mediated exacerbations of airway allergen challenge^{62,64} have recently been developed and used to demonstrate the ability of RV infection to augment airway inflammation caused by allergen sensitization and challenge.

Despite common bacterial infections first being suggested to have a role in asthma exacerbations as early as the 1940s⁶⁵, it was not thought that such infections were important in the pathogenesis of asthma exacerbations⁶⁶ until recently. However, we now realize that patients with asthma have an increased susceptibility to respiratory bacterial infections^{37–39} and increased carriage of pathogenic respiratory bacteria (identified by both culture methods³⁶ and molecular techniques³⁴). Birth cohort studies have shown a link between early-life carriage of the respiratory bacteria *S. pneumoniae*, *H. influenzae* and *M. catarrhalis* and later development of recurrent wheeze in young children born to mothers with

Neutrophilia

An abnormal increase in the number of neutrophils in a body fluid such as bronchoalveolar lavage.

Bronchiectasis

A chronic, irreversible inflammatory condition of the airways, involving tissue destruction and neutrophilic inflammation. Bronchiectasis has a wide range of causes and is associated with bacterial and fungal infections. It can occur in parallel with asthma.




Figure 2 | Viruses and bacteria associated with asthma exacerbations. The prevalence of viruses and bacteria in young children (<2 years old), older children (6–17 years old) and adults, presented as median percentages from several studies (data were obtained from a recent review¹³⁴). Enterovirus estimations in adults and bocavirus estimations in 6–17 year olds and in adults may be under-represented owing to that data not being available in published studies.

asthma⁶⁷. A recent study of the same children showed that acute wheezing episodes during the first 3 years of life are equally associated with both bacterial and viral infections, showing that bacteria may contribute to asthma exacerbations independently of viruses⁶⁸.

The atypical bacteria *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae* are common respiratory pathogens and have also been associated with asthma, wheeze and asthma exacerbations in both adults and children^{69–71}. Detection rates for these bacteria can be as high as 80% in patients with these conditions⁶⁹, and serological positivity rates for these atypical bacteria are often 40–60%^{69,71}, indicating that viral and atypical bacterial infections probably interact to increase the risk of asthma exacerbations. The macrolide antibiotic clarithromycin has previously shown efficacy in patients with stable asthma who are known to be carrying either *M. pneumoniae* or *C. pneumoniae*; in such patients, the drug improves lung function and reduces tumour necrosis factor (TNF) production⁷². More recently, the keto-macrolide telithromycin has shown efficacy in patients with asthma exacerbations, resulting in substantial reductions in the asthma symptom score and improvements in lung function⁷¹. However, the effects of telithromycin were found to be not necessarily related to *C. pneumoniae* or *M. pneumoniae* exposure, suggesting that telithromycin has additional protective properties that are independent of its antibacterial properties.

Microorganism-specific properties

The identification of key microorganisms that are linked with asthma development or asthma pathogenesis raises the important question of which properties of these microorganisms promote asthma. The microorganisms that commonly infect different areas of the lower airway are shown in FIG. 3. Some of these microorganisms may be found systemically in more

severe disease, as has been shown for RVs⁷³. A key feature of a microorganism in promoting asthma is the ability to induce lung inflammation, injury, or repair and remodelling. Many of the innate receptors that recognize respiratory fungi, viruses or bacteria, including TLRs, RIG-I-like helicases and NOD-like receptors, activate the nuclear factor-κB (NF-κB) family of transcription factors, which induce more than 100 pro-inflammatory and host response genes⁷⁴. RSV and RVs induce a range of pro-inflammatory cytokines, chemokines, growth factors, adhesion molecules and mucins. Mucins cause mucous plugging of the airway and may provide a substrate for bacterial colonization, whereas cytokines facilitate cellular chemotaxis, and activation and proliferation of immune cells in the infected airway^{45,75}. Microorganisms may damage and compromise the integrity of the airway by infecting airway epithelial cells, causing cell death⁷⁶ and shedding⁷⁷. They can also affect epithelial permeability, leading to increased airway inflammation and creating opportunities for increased infection⁷⁸, allergen uptake⁷⁹ or exposure to environmental pollutants, all of which are important contributing factors in asthma (FIG. 4).

Respiratory pathogens can also induce mediators that are required for airway repair, resulting in airway scarring or remodelling. These processes include angiogenesis, increased ASM proliferation and hypertrophy, and thicker basement membranes owing to collagen and fibronectin deposition, as well as the generation of new lymphatic vessels that ultimately result in thicker airway walls and reduced lung function. Whether or not viral or bacterial infections directly initiate this process is unclear; however, what is clear is that respiratory infections, including by *Mycoplasma pulmonis*, RVs, RSV and *A. fumigatus* spores, can induce some of these pro-angiogenic mediators, including fibroblast growth factors and vascular endothelial growth factors^{80–82}, and the structural proteins perlecan (also known as HSPG) and collagen⁸³, the building blocks of airway remodelling.

Microorganisms and asthma treatment

Asthma treatment often requires daily treatment with a range of immunomodulatory or immunosuppressive agents, such as macrolide antibiotics or glucocorticoids, suggesting another way that microorganisms interact with asthma. Surprisingly, scant attention has been paid to the possible effects of such treatments on an individual’s microbiota and their antimicrobial responses. However, some studies provide indirect evidence for an immunosuppressive effect. For example, increases in bacterial pneumonia have been noted in patients with COPD who are treated with glucocorticoid therapy⁸⁴. Furthermore, an increased incidence of upper respiratory tract infections following treatment with the leukotriene receptor antagonist montelukast has been reported in young children with asthma⁸⁵. It is also interesting to speculate whether the fact that asthma is a risk factor for IPI, as previously discussed, is directly attributable to asthma therapies such as glucocorticoids. Conversely, there is some experimental evidence suggesting that the action of glucocorticoids confers benefits

Cytopathology

Changes that occur to a tissue, at the single-cell level, during disease. Viral infections typically cause cytopathology in cultured cells, and this can be used as a diagnostic marker.

Surfactant

A substance that interferes with the association of two liquids or a solid and a liquid. Detergents are surfactants that function by lowering the surface tension of liquids.

Adjuvants

Substances that enhance adaptive immune responses (both B cell and T cell responses) to immunogens. Adjuvants are not recognized by T cells or B cells themselves but may function by activating specific cells or acting as a long-term depot for slow and effective immunogen release.

to antimicrobial immunity. *In vitro*, glucocorticoids have been shown to induce a number of antimicrobial peptides, pentraxins, collectins and complement proteins⁸⁶. Furthermore, clinical studies support the benefits of glucocorticoid use: in preschool children, the use of glucocorticoids for 2 years reduces asthma exacerbations (as measured by exacerbations that require systemic glucocorticoid administration and hospital admissions)⁸⁷.

Although several studies support the use of macrolide antibiotics for the treatment of atypical pathogens in patients with asthma exacerbations⁸⁸, it is important to consider how the microbiome is affected by macrolides or other antibiotics and how this might affect asthma and the host responses to infection. Treatment of mice with the antibiotics vancomycin, neomycin, metronidazole and ampicillin greatly changes their airway and gut microbiome and impairs their antiviral responses to influenza viruses³⁵. In human studies, it is currently unclear whether the genera that seem to colonize the airways of patients with asthma or COPD and of individuals without asthma or COPD differ because of treatment-specific effects³⁴. More research is needed to understand whether the microbiome of patients with asthma is actually a consequence of active therapy. Further large clinical trials with such treatments are required to understand the relationships between microorganisms and asthma treatments.

Host responses and asthma

Infections or environmental stresses may induce alterations in epithelial cells and underlying stromal cells, and these alterations may modify the response of these cells to further stimulation or may influence barrier function. For example, enhanced permeability caused by virus-induced cytopathology may lead to inhaled allergens, pollutants and other irritants having greater access to basal cells and the underlying airway tissue, which could be detrimental because submucosal antigen-presenting cells (APCs) are not restrained like their airway lumen counterparts. Epithelial cells orchestrate innate immune regulation in the airway lumen, preventing an inflammatory response to non-injurious stimuli by controlling TLR signalling and phagocytosis through the expression of surfactant proteins⁸⁹. Epithelial cells also express mucin 1 (MUC1), which suppresses alveolar macrophage responses by binding to TLRs⁹⁰.

IL-10 and transforming growth factor- β (TGF β) from airway epithelial cells can influence the immune milieu by raising the threshold of activation of airway macrophages⁹¹ and driving the expression of the inhibitory receptor CD200R on alveolar macrophages. The ligand for CD200R, CD200 (also known as OX2), is expressed on the luminal aspect of the airway epithelium, and the interaction of these two proteins prevents the activation of alveolar macrophages in the presence or absence of inflammatory stimuli⁹². Thus, macrophages in the airspaces are less proficient at antigen presentation than submucosal macrophages, are poorly phagocytic and secrete prostaglandins and TGF β to reduce T cell responses, leading to reversible T cell inactivation⁹³. Alveolar macrophages also actively inhibit interdigitating dendritic cells (DCs) in the airways⁹⁴, which in turn secrete IL-10. APCs in the submucosal tissues are less restrained by these factors simply because the cells are not exposed to these epithelium-derived innate suppressors. Should any of these pathways be altered through infection, the less restrained APCs may recognize innocuous antigens or allergens, ultimately contributing to inflammation and disease.

Recognition of respiratory microorganisms by pattern recognition receptors can inadvertently initiate or exacerbate an unrelated inflammatory condition. For instance, TLR agonists may act as microbial adjuvants that enhance the recognition of concurrent allergens⁹⁵. The major cat allergen Fel d 1 is often contaminated with TLR ligands derived from microorganisms found in the feline oral cavity, and the house dust mite often contains the commensal fungus *Aspergillus penicillioides*, which activates TLR2 and TLR4. These allergen preparations can contain DNA from Gram-negative microorganisms^{96,97}. The relationship between TLRs and allergens has recently become more complex, with evidence showing that allergens themselves may be direct TLR agonists^{98,99}. Molecular mimicry between allergens and microbial components¹⁰⁰ raises the idea that TLR-mediated recognition of allergens may be an important part of sensitization to these molecules.

Infection also causes the recruitment of APCs in high numbers and for long periods following pathogen




Figure 3 | Microorganisms involved in asthma and their niches. A cross-section of the human lower respiratory tract, showing sites of infection for different microorganisms and the effects that they have on airway function.




Figure 4 | Viruses and bacteria induce airway inflammation. Bacterial and viral infections of the airways activate immune and structural cells, promoting inflammation and influencing responses to other pathogens, allergens and pollution. Infection of airway epithelium by both viruses and bacteria induces neutrophil chemokines (CXC-chemokine ligand 1 (CXCL1; also known as GROα), CXCL5 (also known as ENA78) and CXCL8 (also known as IL-8)), and T helper 1 (T_H1) type chemokines (CC-chemokine ligand 5 (CCL5; also known as RANTES), CXCL10 (also known as IP10) and CXCL11 (also known as ITAC)), and increases epithelial permeability. Neutrophils secrete several mediators that can contribute to inflammation and the integrity of the airway, including matrix metalloproteinases (MMPs), elastase and reactive oxygen species (ROS). Epithelial cells normally express luminal CD200, which, when bound to its receptor, CD200R, on lumen macrophages, prevents the macrophage response to inflammatory stimuli. Lumen macrophages are normally inhibitory, as they produce transforming growth factor-β (TGFβ), which inhibits inflammatory airway dendritic cells (DCs). A higher epithelial permeability or epithelial damage as a result of infection allows the unrestrained submucosal macrophages access to the allergen and to other stimuli, and this can promote overzealous inflammation. Submucosal macrophages and epithelial cells are triggered by exposure to bacteria or viruses (and their products) to produce interleukin-1β (IL-1β), IL-6 and tumour necrosis factor (TNF), which promote inflammation. ASM, airway smooth muscle; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon-γ; MHC, major histocompatibility complex; T_H1, T helper 1.

clearance. For example, cells expressing CD11c (also known as integrin αX) display enhanced antigen presentation long after the resolution of an acute infection by influenza virus or RSV^{101,102}. Such cells are long lasting¹⁰³, suggesting that an enhanced mature APC compartment assists immunological responses on subsequent exposure to environmental allergens. This would also be facilitated by an increase in tertiary lymphoid tissue in the lung parenchyma, which is a common feature following respiratory tract infection¹⁰⁴, in human asthma¹⁰⁵ and in experimental mouse models of asthma¹⁰⁶.

Successive infections may also alter the lung environment and affect the delicate balance between host, pathogen and chronic airway disease. Bacterial infections are known to follow influenza virus infections; indeed, many of the individuals who died in the influenza pandemics exhibited coexisting bacterial pneumonia¹⁰⁷. This has implications for asthma: what is assumed to be a virus-induced asthma exacerbation may in fact include a secondary bacterial infection. Data suggesting that this does occur have been reported for *C. pneumoniae*⁶⁹, but further studies are required to determine whether secondary bacterial infections commonly follow viral infections in asthma. Thus, by causing barrier disruption, viruses may initiate a cascade that, as described above, allows environmental bacteria better access to the underlying tissue (FIG. 4).

Microorganism and host factor synergy

T helper 2 type immunity. T_H2 cells are CD4⁺ T cells that produce a defined array of cytokines — classically, IL-4,

IL-5, IL-9 and IL-13 — and home to sites of inflammation. T_H2 cells are involved in defence against gastrointestinal nematodes and are also strongly implicated in the pathogenesis of asthma and asthma exacerbations. Case control studies show a clear link between respiratory virus infection together with allergen exposure in sensitized children¹⁰⁸ and adults¹⁰⁹ in increasing the risk of hospital admissions due to asthma exacerbations. Furthermore, experimental RV infection models have shown that patients with asthma have more severe lower respiratory tract symptoms and greater reductions in lung function than control patients, and have increases in bronchial hyper-reactivity⁷⁵. Exacerbation severity is strongly correlated with both T_H2 type cytokine production from BAL CD4⁺ T cells and viral load. RV infection in mouse asthma models supports these observations, as RVs enhance T_H2 type cytokine production by sensitized mice that are simultaneously challenged with aero-allergen⁶². How viral infection can synergize with or act additively to T_H2 type immunity is shown in FIG. 5.

Excessive T_H2 type responses are implicated in the pathogenesis of RSV-mediated bronchiolitis¹¹⁰, and increased production of IL-5 by T cells at birth is associated with a greater risk of severe respiratory infection¹¹¹. Genetic associations also link polymorphisms in the T_H2 gene locus to severe RSV-mediated disease^{112,113}. Increased T_H2 type responses are reported in peripheral blood mononuclear cells and sputum preceding acute asthma exacerbations *in vivo* and also in mixed T_H1–T_H2 cell populations during acute exacerbations *in vivo*¹¹⁴.

Tertiary lymphoid tissue
Lymphoid tissue that develops only after stimulation with antigen, such as in the process of inflammation. The lymphocytes of tertiary lymphoid tissue are typically derived from primary or secondary lymphoid tissue.

Parenchyma
The body or bulk of a tissue, such as the lungs. The lung parenchyma typically encompasses the alveoli and cells within.




Figure 5 | Respiratory viruses interact with allergens in an additive or synergistic manner, promoting asthma. Following sensitization, allergen presentation by airway dendritic cells (DCs) facilitates the promotion of T helper 2 (T_H2) cells. Viruses infect epithelial cells, stimulating the release of T_H2 cell-promoting chemokines CC-chemokine ligand 17 (CCL17) and CCL22, and cytokines thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25) and IL-33. The T_H2 type chemokines attract T_H2 cells into the airway, and these in turn secrete IL-4, IL-5 and IL-13. IL-5 promotes eosinophilia, and the resultant eosinophils release the inflammatory mediators major basic protein (MBP), eosinophil cationic protein (ECP) and transforming growth factor- β (TGF β), inducing inflammation in the airway smooth muscle (ASM). IL-4 and IL-13 cause antibody class switching to immunoglobulin E in B cells, so that B cells secrete allergen-specific IgE. This antibody then binds mast cells, and crosslinking of the allergen on mast cell-bound IgE causes mast cell degranulation and release of preformed mediators, including histamine, prostaglandin (PGD₂) and leukotrienes (LTC₄, LTD₄ and LTE₄). These mediators cause bronchoconstriction and further airway inflammation. Mast cells also produce the T_H2 cytokines IL-4 and IL-13, as well as other cytokines, including TGF β and tumour necrosis factor (TNF), promoting further T_H2 type immune responses and inflammation.

T_H2 type immunity encompasses structural cells in addition to T_H2 -polarized CD4⁺ T cells. Bronchial epithelial cells (BECs) express CC-chemokine ligand 17 (CCL17; also known as TARC), a chemokine that binds with high affinity to CC-chemokine receptor 4 (CCR4), which is abundantly expressed on T_H2 cells. In mice, RSV was found to induce CCL17 production, and this finding was reinforced in a T_H2 -biasing model in which mice were first vaccinated with recombinant vaccinia virus expressing RSV major surface glycoprotein G and then infected with RSV¹¹⁵. *In vitro*, production of CCL17 by human BECs infected with human RSV requires the presence of T_H2 type cytokines and is associated with activation of both NF- κ B and STAT6 (signal transducer and activator of transcription 6)¹¹⁵. Recently, the signalling molecule endoplasmic reticulum IFN stimulator (ERIS; also known as TMEM173) has been shown to induce STAT6 activation in viral infections¹¹⁶, providing a potential mechanism for how viruses induce T_H2 type cytokines or chemokines.

Thymic stromal lymphopoietin (TSLP) is a T_H2 cell-promoting cytokine that is produced by BECs and can be induced by both bacterial (TLR2 and TLR9 activating) and viral (TLR3 and TLR8 activating) ligands¹¹⁷. This cytokine matures the DC network and, in humans, enhances the cytolytic activity of CD8⁺ T cells and the

production of T_H2 type cytokines, leading to enhanced airway hyper-reactivity. Furthermore, mast cells in the bronchial mucosa of patients with asthma express the TSLP receptor. Together with IL-1, supernatants from TLR2-activated airway epithelial cells induce mast cell production of IL-5 and IL-13, which have pivotal roles in the development and maintenance of asthma¹¹⁷. Both RV- and RSV-infected BECs produce TSLP. Human RSV-induced TSLP production stimulates DC expression of the T_H2 -associated molecules CCL17 and OX40 ligand (OX40L; also known as TNFSF4)¹¹⁸. RV-induced TSLP production is synergistically enhanced by IL-4 (REF. 119). BECs from patients with asthma also produce higher levels of TSLP than BECs from healthy individuals when polyinosinic-polycytidylic acid stimulation is used as a surrogate for viral infection¹²⁰. Thus, by producing TSLP in response to infection, the airway epithelium may orchestrate the pathophysiology of asthma.

IL-25 is structurally related to members of the IL-17 cytokine family but, like TSLP, is another T_H2 cell-amplifying cytokine that is expressed by a number of different cells, including BECs. A recent study using a mouse RSV infection model demonstrated the importance of IL-25 in regulating airway disease following viral infection. Natural killer cell-depleted mice exhibit

enhanced T_H2 type airway inflammation following RSV infection. Using an IL-25-neutralizing antibody, this RSV-specific T_H2 cell-skewed response was shown to be dependent on IL-25 production by airway epithelial cells¹²¹.

Allergen-specific IgE is a key mediator in allergic reactions and has a central role in the pathogenesis of asthma. IL-4 and IL-13 stimulate the production of IgE, which binds allergen, allowing crosslinking of IgE receptors on mast cells and basophils; this causes the release of mediators that have profound effects on airway inflammation and hyper-reactivity. Analysis of nasal secretions from RSV-infected infants revealed the presence of RSV-specific IgE, and IgE levels were found to positively correlate with wheeze and higher levels of histamine¹²², although these studies have been hard to replicate. In mice, primary RSV infection is usually dominated by T_H1 type effects but may induce IL-4 and IL-13 expression in the lungs as well as the production of RSV-specific IgE in serum under some conditions. Transfer of RSV-specific IgE to naive mice increases airway hyper-reactivity following RSV infection, an effect that is dependent on expression of high-affinity IgE receptor¹²³. RSV infection in neonatal mice also induces T_H2 type cytokine-dependent RSV-specific IgE. Re-infection with RSV 5 weeks later induces a T_H2 cell-skewed immune response that is reduced in magnitude by IgE-specific antibody therapy¹²⁴. A mechanism has been proposed to explain how IgE against a related paramyxovirus, Sendai virus (SeV), enhances T_H2 cell-associated airway disease in mice. This suggested mechanism involves infection-induced upregulation of high-affinity IgE receptor on conventional lung DCs. The authors speculate that the later appearance of SeV-specific IgE, after viral clearance, crosslinks IgE receptors (with viral antigen) on conventional DCs, stimulating the production of CCL28, which in turn recruits activated IL-13-producing T_H2 cells to the lung¹²⁵.

Although there is still much to learn, it has become clear that understanding how respiratory infections interact with T_H2 type immunity, thereby increasing the severity of allergic airway inflammation, may provide opportunities for the development of novel strategies to treat asthma. Therapies targeting T_H2 type immunity and IgE (TABLE 2) are already yielding encouraging results.

Increased susceptibility to viruses, bacteria or fungi in asthma. The idea that patients with asthma might be more susceptible to viral infections than healthy individuals first surfaced through the study of co-habiting spouse pairs with and without asthma¹²⁶. Although individuals with and without asthma had the same incidence of RV infections, individuals with asthma had lower respiratory tract symptoms for longer than individuals without asthma, and had an increased severity of symptoms.

Cultured primary BECs from adults with allergic asthma exhibit lower levels of RV-induced IFN β (a type I IFN), lower levels of virus-induced apoptosis and higher RV loads than cells from control adults¹²⁷. A deficiency in the antiviral type III IFNs, IFN λ 1 (also known as IL-29), IFN λ 2 (also known as IL-28A) and IFN λ 3 (also known as IL-28B), has also been described¹²⁸. IFNs may therefore be protective against RV-induced asthma exacerbations. However, two similar studies failed to see any difference between individuals with and without asthma regarding RV-induced IFN expression in similar model systems^{129,130}, suggesting that impaired IFN expression is a feature of a subset of patients with asthma. These studies raise the possibility of using IFN β and IFN λ s as therapeutics against asthma exacerbations.

Although epidemiological data clearly show that asthma is a risk factor for IPI, there are few studies that have considered a mechanistic rationale for this. Genome-wide association studies in individuals with asthma or atopy do, however, highlight polymorphisms in innate immune genes such as those encoding TLRs and transcription factors, and such polymorphisms potentially explain the increased susceptibility of these individuals to viruses, bacteria and fungi^{131–133}. Deficiencies in the T_H1 type cytokines IFN γ and IL-12 in patients with asthma⁷⁵ also suggest that impaired host defence responses to bacteria are probably implicated. An understanding of how these genetic and cytokine differences affect host susceptibility to infection may help in establishing new therapies for asthma.

Conclusion

Advances in molecular microbiology offer new avenues by which to discover the roles of microorganisms in asthma pathogenesis and exacerbation. There is now overwhelming evidence that asthma can be viewed as a chronic inflammatory condition which is initiated, triggered and maintained by the respiratory microbiota. Microorganisms have roles in the onset and development of asthma but can also be protective (the hygiene hypothesis). It is not yet clear whether some organisms (especially RSV) actually cause atopic disease or are instead associated with atopy because individuals who are prone to atopy suffer more from infantile bronchiolitis. Viruses undoubtedly cause most asthma exacerbations, but some non-viral pathogens may also play a part. Certain fungi and bacteria have diverse roles in driving the pathogenesis and increasing the severity of asthma, and various microorganisms play different parts in different asthma endophenotypes. More research is needed, but our ultimate goal is to identify microbial targets that are amenable to manipulation with vaccines or antimicrobial drugs and thus to reduce the burden of asthma on society.

1. Bateman, E. D. *et al.* Global strategy for asthma management and prevention: GINA executive summary. *Eur. Respir. J.* **31**, 143–178 (2008).
2. Wenzel, S. E. Asthma: defining of the persistent adult phenotypes. *Lancet* **368**, 804–813 (2006).
3. Lotvall, J. & Svedmyr, N. Salmeterol: an inhaled β 2-agonist with prolonged duration of action. *Lung* **171**, 249–264 (1993).

4. Matricardi, P. M. *et al.* Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. *BMJ* **320**, 412–417 (2000).
5. Leonardi-Bee, J., Pritchard, D. & Britton, J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. *Am. J. Respir. Crit. Care Med.* **174**, 514–523 (2006).

6. Okada, H., Kuhn, C., Feillet, H. & Bach, J. F. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. *Clin. Exp. Immunol.* **160**, 1–9 (2010).
 7. Ege, M. J. *et al.* Exposure to environmental microorganisms and childhood asthma. *N. Engl. J. Med.* **364**, 701–709 (2011).
- This study shows that microbial diversity is inversely related to the risk of developing asthma.**

8. Strachan, D. P. Family size, infection and atopy: the first decade of the "hygiene hypothesis". *Thorax* **55** (Suppl. 1), S2–S10 (2000).
9. Martinez, F. D. The coming-of-age of the hygiene hypothesis. *Respir. Res.* **2**, 129–132 (2001).
10. Pakarinen, J. *et al.* Predominance of Gram-positive bacteria in house dust in the low-allergy risk Russian Karelia. *Environ. Microbiol.* **10**, 3317–3325 (2008).
11. Rintala, H., Pitkaranta, M., Toivola, M., Paulin, L. & Nevalainen, A. Diversity and seasonal dynamics of bacterial community in indoor environment. *BMC Microbiol.* **8**, 56 (2008).
12. Lee, L., Tin, S. & Kelley, S. T. Culture-independent analysis of bacterial diversity in a child-care facility. *BMC Microbiol.* **7**, 27 (2007).
13. Nembrini, C. *et al.* Bacterial-induced protection against allergic inflammation through a multicomponent immunoregulatory mechanism. *Thorax* **66**, 755–763 (2011).
14. Conrad, M. L. *et al.* Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe *Acinetobacter lwoffii* F78. *J. Exp. Med.* **206**, 2869–2877 (2009).
15. Maslowski, K. M. *et al.* Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* **461**, 1282–1286 (2009).
16. Hall, C. B. *et al.* The burden of respiratory syncytial virus infection in young children. *N. Engl. J. Med.* **360**, 588–598 (2009).
17. Palmenberg, A. C. *et al.* Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. *Science* **324**, 55–59 (2009). **Complete sequencing of 99 serotypes of RVs identifies conserved RNA motifs and clade-specific diversity, and reveals a new species of RV, RV-D.**
18. Lau, S. K. *et al.* Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. *J. Clin. Microbiol.* **45**, 3655–3664 (2007).
19. Bochkov, Y. A. *et al.* Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. *Nature Med.* **17**, 627–632 (2011). **The first study to successfully recover and culture RV-C using reverse genetics. The data point to a unique tropism of RV-C and suggest that it uses an as-yet-unidentified receptor.**
20. Makela, M. J. *et al.* Viruses and bacteria in the etiology of the common cold. *J. Clin. Microbiol.* **36**, 539–542 (1998).
21. Lemanske, R. F. Jr *et al.* Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J. Allergy Clin. Immunol.* **116**, 571–577 (2005).
22. Guilbert, T. W. *et al.* Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. *J. Allergy Clin. Immunol.* **128**, 532–538.e10 (2011).
23. Jackson, D. J. *et al.* Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am. J. Respir. Crit. Care Med.* **178**, 667–672 (2008).
24. Henderson, J. *et al.* Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. *Pediatr. Allergy Immunol.* **16**, 386–392 (2005).
25. Carroll, K. N. *et al.* The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. *J. Allergy Clin. Immunol.* **123**, 1055–1061.e1 (2009).
26. Smyth, R. L. & Openshaw, P. J. Bronchiolitis. *Lancet* **368**, 312–322 (2006).
27. Illi, S. *et al.* Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. *Lancet* **368**, 763–770 (2006).
28. Sigurs, N. *et al.* Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax* **65**, 1045–1052 (2010). **This analysis of human RSV-infected children shows that severe early human RSV-mediated bronchiolitis is associated with an increased prevalence of allergic asthma persisting into early adulthood.**
29. Pala, P. *et al.* Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. *Eur. Respir. J.* **20**, 376–382 (2002).
30. Culley, F. J., Pollott, J. & Openshaw, P. J. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. *J. Exp. Med.* **196**, 1381–1386 (2002). **This investigation elegantly demonstrates that neonatal infection with RSV in mice causes increased disease severity on reinfection later in life. The increased severity is associated with enhanced T_H2 type responses.**
31. Simoes, E. A. *et al.* Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. *J. Pediatr.* **151**, 34–42.e1 (2007).
32. Simoes, E. A. *et al.* The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. *J. Allergy Clin. Immunol.* **126**, 256–262 (2010).
33. Jackson, D. J. *et al.* Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. *Am. J. Respir. Crit. Care Med.* **185**, 281–285 (2011). **This birth cohort study of children at risk for asthma in later life establishes that there is a sequential relationship between RV infection and allergic sensitization, with allergic sensitization occurring before RV infection.**
34. Hilty, M. *et al.* Disordered microbial communities in asthmatic airways. *PLoS ONE* **5**, e8578 (2010). **This work establishes that the lower airway is not sterile and contains a distinct microbiota. In asthma, this microbiota changes and becomes enriched in pathogenic proteobacteria, particularly Haemophilus spp.**
35. Ichinoh, T. *et al.* Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc. Natl Acad. Sci. USA* **108**, 5354–5359 (2011).
36. Jouni, U. *et al.* Pneumococcal carriage is more common in asthmatic than in non-asthmatic young men. *Clin. Respir. J.* **4**, 222–229 (2010).
37. Klemets, P. *et al.* Risk of invasive pneumococcal infections among working age adults with asthma. *Thorax* **65**, 698–702 (2010). **This study demonstrates that adults with asthma are at high risk for invasive pneumococcal infection.**
38. Talbot, T. R. *et al.* Asthma as a risk factor for invasive pneumococcal disease. *N. Engl. J. Med.* **352**, 2082–2090 (2005).
39. Pilshvili, T. *et al.* Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. *Pediatrics* **126**, e9–e17 (2010).
40. O'Hollaren, M. T. *et al.* Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. *N. Engl. J. Med.* **324**, 359–363 (1991).
41. Bowyer, P., Fraczek, M. & Denning, D. W. Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. *BMC Genomics* **7**, 251 (2006).
42. Oliveira, M., Ribeiro, H., Delgado, J. L. & Abreu, I. The effects of meteorological factors on airborne fungal spore concentration in two areas differing in urbanisation level. *Int. J. Biometeorol.* **53**, 61–73 (2009).
43. Pulimood, T. B., Corden, J. M., Bryden, C., Sharples, L. & Nasser, S. M. Epidemic asthma and the role of the fungal mold *Alternaria alternata*. *J. Allergy Clin. Immunol.* **120**, 610–617 (2007).
44. Madowell, A. L. & Peters, S. P. Neutrophils in asthma. *Curr. Allergy Asthma Rep.* **7**, 464–468 (2007).
45. Pizzichini, M. M. *et al.* Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. *Am. J. Respir. Crit. Care Med.* **158**, 1178–1184 (1998).
46. Wark, P. A. *et al.* Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. *Eur. Respir. J.* **19**, 68–75 (2002).
47. Johnston, S. L. *et al.* Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. *J. Immunol.* **160**, 6172–6181 (1998).
48. Wood, L. G., Simpson, J. L., Hansbro, P. M. & Gibson, P. G. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. *Free Rad. Res.* **44**, 146–154 (2009).
49. Huang, Y. J. *et al.* Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. *J. Allergy Clin. Immunol.* **127**, 372–381.e3 (2011). **This investigation finds that members of the Comamonadaceae, Sphingomonadaceae, Oxalobacteraceae and other bacterial families are highly correlated with bronchial hyper-reactivity in poorly controlled asthma.**
50. O'Driscoll, B. R., Hopkinson, L. C. & Denning, D. W. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. *BMC Pulm. Med.* **5**, 4 (2005).
51. O'Driscoll, B. R. *et al.* Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. *Clin. Exp. Allergy* **39**, 1677–1683 (2009).
52. Denning, D. W. *et al.* Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. *Am. J. Respir. Crit. Care Med.* **179**, 11–18 (2009).
53. Wark, P. A. *et al.* Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. *Eur. Respir. J.* **16**, 1095–1101 (2000).
54. Patterson, R., Rosenberg, M. & Roberts, M. Evidence that *Aspergillus fumigatus* growing in the airway of man can be a potent stimulus of specific and nonspecific IgE formation. *Am. J. Med.* **63**, 257–262 (1977).
55. Kodzius, R. *et al.* Rapid identification of allergen-encoding cDNA clones by phage display and high-density arrays. *Comb. Chem. High Throughput Screen.* **6**, 147–154 (2003).
56. Nierman, W. C. *et al.* Genomic sequence of the pathogenic and allergenic filamentous fungus *Aspergillus fumigatus*. *Nature* **438**, 1151–1156 (2005).
57. Aimanian, V. *et al.* Surface hydrophobin prevents immune recognition of airborne fungal spores. *Nature* **460**, 1117–1121 (2009).
58. Brock, M. *et al.* Bioluminescent *Aspergillus fumigatus*, a new tool for drug efficiency testing and *in vivo* monitoring of invasive aspergillosis. *Appl. Environ. Microbiol.* **74**, 7023–7035 (2008).
59. Pasqualotto, A. C., Powell, G., Niven, R. & Denning, D. W. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. *Respirology* **14**, 1121–1127 (2009).
60. Johnston, N. W. *et al.* The September epidemic of asthma exacerbations in children: a search for etiology. *J. Allergy Clin. Immunol.* **115**, 132–138 (2005). **This study shows (retrospectively) the recurring nature of acute hospitalizations associated with asthma in September and that viral infections (mostly by picornaviruses) are associated with this epidemic.**
61. Johnston, S. L. *et al.* Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *BMJ* **310**, 1225–1229 (1995).
62. Bartlett, N. W. *et al.* Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. *Nature Med.* **14**, 199–204 (2008). **The first report of a mouse model of RV infection and RV-mediated exacerbation of allergic airway inflammation, using both wild-type and transgenic mice expressing chimeric mouse-human ICAM1, the RV major group receptor.**
63. Newcomb, D. C. *et al.* Human rhinovirus 1B exposure induces phosphatidylinositol 3-kinase-dependent airway inflammation in mice. *Am. J. Respir. Crit. Care Med.* **177**, 1111–1121 (2008).
64. Nagarkar, D. R. *et al.* Rhinovirus infection of allergen-sensitized and -challenged mice induces eotaxin release from functionally polarized macrophages. *J. Immunol.* **185**, 2525–2535 (2010).
65. Heise, H. A. The role of streptococci in bronchial asthma; etiologic significance and treatment with *Streptococcus* filtrates. *Ann. Allergy* **7**, 240–249 (1949).
66. Pattemore, P. K., Johnston, S. L. & Bardin, P. G. Viruses as precipitants of asthma symptoms. I. Epidemiology. *Clin. Exp. Allergy* **22**, 325–336 (1992).
67. Bisgaard, H. *et al.* Childhood asthma after bacterial colonization of the airway in neonates. *N. Engl. J. Med.* **357**, 1487–1495 (2007).
68. Bisgaard, H. *et al.* Association of bacteria and viruses with wheeze episodes in young children: prospective birth cohort study. *BMJ* **341**, c4978 (2010). **This work demonstrates the potentially important role of bacteria in wheeze in children with and without a viral infection.**
69. Wark, P. A., Johnston, S. L., Simpson, J. L., Hensley, M. J. & Gibson, P. G. *Chlamydia pneumoniae* immunoglobulin A reactivation and airway inflammation in acute asthma. *Eur. Respir. J.* **20**, 834–840 (2002).
70. Cunningham, A. F., Johnston, S. L., Juliano, S. A., Lampe, F. C. & Ward, M. E. Chronic *Chlamydia pneumoniae* infection and asthma exacerbations in children. *Eur. Respir. J.* **11**, 345–349 (1998).

71. Johnston, S. L. *et al.* The effect of telithromycin in acute exacerbations of asthma. *N. Engl. J. Med.* **354**, 1589–1600 (2006).
This study shows the protective effects of the ketomacrolide antibiotic telithromycin in asthma exacerbations, suggesting that targeting atypical bacteria with anti-infectives protects against asthma exacerbations.
72. Kraft, M., Cassell, G. H., Pak, J. & Martin, R. J. *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in asthma: effect of clarithromycin. *Chest* **121**, 1782–1788 (2002).
73. Xatzipsalti, M. *et al.* Rhinovirus viremia in children with respiratory infections. *Am. J. Respir. Crit. Care Med.* **172**, 1037–1040 (2005).
74. O'Neill, L. A. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nature Rev. Immunol.* **7**, 353–364 (2007).
75. Message, S. D. *et al.* Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. *Proc. Natl Acad. Sci. USA* **105**, 13562–13567 (2008).
76. Bossios, A. *et al.* Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. *Respir. Res.* **6**, 114 (2005).
77. Turner, R. B., Hendley, J. O. & Gwaltney, J. M. Jr. Shedding of infected ciliated epithelial cells in rhinovirus colds. *J. Infect. Dis.* **145**, 849–853 (1982).
78. Bassetti, S. *et al.* Dispersal of *Staphylococcus aureus* into the air associated with a rhinovirus infection. *Infect. Control Hosp. Epidemiol.* **26**, 196–203 (2005).
79. Marsland, B. J., Scanga, C. B., Kopf, M. & Le Gros, G. Allergic airway inflammation is exacerbated during acute influenza infection and correlates with increased allergen presentation and recruitment of allergen-specific T-helper type 2 cells. *Clin. Exp. Allergy* **34**, 1299–1306 (2004).
80. Volonaki, E. *et al.* Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors. *Clin. Exp. Allergy* **36**, 1268–1273 (2006).
81. Tourdot, S. *et al.* Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. *Clin. Exp. Allergy* **38**, 1016–1024 (2008).
82. Baluk, P. *et al.* Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. *J. Clin. Invest.* **115**, 247–257 (2005).
83. Kuo, C. *et al.* Rhinovirus infection induces extracellular matrix protein deposition by primary bronchial epithelial cells and lung fibroblasts. *Respirology* **16**, 367–377 (2011).
84. Calverley, P. M. *et al.* Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N. Engl. J. Med.* **356**, 775–789 (2007).
85. Bisgaard, H. *et al.* Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. *Pediatr. Pulmonol.* **44**, 568–579 (2009).
86. Zhang, N., Truong-Tran, Q. A., Tancoway, B., Harris, K. E. & Schleimer, R. P. Glucocorticoids enhance or spare innate immunity: effects in airway epithelium are mediated by CCAAT/enhancer binding proteins. *J. Immunol.* **179**, 578–589 (2007).
87. Guilbert, T. W. *et al.* Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N. Engl. J. Med.* **354**, 1985–1997 (2006).
88. Blasi, F. & Johnston, S. L. The role of antibiotics in asthma. *Int. J. Antimicrob. Agents* **29**, 485–493 (2007).
89. Henning, L. N. *et al.* Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages. *J. Immunol.* **180**, 7847–7858 (2008).
90. Ueno, K. *et al.* MUC1 mucin is a negative regulator of Toll-like receptor signaling. *Am. J. Respir. Cell. Mol. Biol.* **38**, 263–268 (2008).
91. Fernandez, S., Jose, P., Avdiushko, M. G., Kaplan, A. M. & Cohen, D. A. Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists. *J. Immunol.* **172**, 2613–2620 (2004).
92. Snelgrove, R. J. *et al.* A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. *Nature Immunol.* **9**, 1074–1083 (2008).
93. Balbo, P., Silvestri, M., Rossi, G. A., Crimi, E. & Burastero, S. E. Differential role of CD80 and CD86 on alveolar macrophages in the presentation of allergen to T lymphocytes in asthma. *Clin. Exp. Allergy* **31**, 625–636 (2001).
94. Holt, P. G. *et al.* Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells *in vivo* by resident alveolar macrophages. *J. Exp. Med.* **177**, 397–407 (1993).
95. Eisenbarth, S. C. *et al.* Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. *J. Exp. Med.* **196**, 1645–1651 (2002).
96. Valerio, C. R., Murray, P., Arlian, L. G. & Slater, J. E. Bacterial 16S ribosomal DNA in house dust mite cultures. *J. Allergy Clin. Immunol.* **116**, 1296–1300 (2005).
97. Phipps, S., Lam, C. E., Foster, P. S. & Mattheai, K. I. The contribution of Toll-like receptors to the pathogenesis of asthma. *Immunol. Cell Biol.* **85**, 463–470 (2007).
98. Li, D. Q. *et al.* Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways. *J. Allergy Clin. Immunol.* **128**, 1318–1325 (2011).
99. Hammad, H. *et al.* House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nature Med.* **15**, 410–416 (2009).
100. Trompette, A. *et al.* Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. *Nature* **457**, 585–588 (2009).
101. Beyer, M. *et al.* Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. *J. Allergy Clin. Immunol.* **113**, 127–133 (2004).
102. Kirby, A. C., Newton, D. J., Carding, S. R. & Kaye, P. M. Pulmonary dendritic cells and alveolar macrophages are regulated by $\gamma\delta$ T cells during the resolution of *S. pneumoniae*-induced inflammation. *J. Pathol.* **212**, 29–37 (2007).
103. Amano, H. *et al.* Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia. *J. Immunol.* **172**, 398–409 (2004).
104. Moyron-Quiroz, J. E. *et al.* Role of inducible bronchus associated lymphoid tissue (iBAL) in respiratory immunity. *Nature Med.* **10**, 927–934 (2004).
105. Elliot, J. G. *et al.* Aggregations of lymphoid cells in the airways of nonsmokers, smokers, and subjects with asthma. *Am. J. Respir. Crit. Care Med.* **169**, 712–718 (2004).
106. Lee, J. J. *et al.* Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. *J. Exp. Med.* **185**, 2143–2156 (1997).
107. Morens, D. M. & Fauci, A. S. The 1918 influenza pandemic: insights for the 21st century. *J. Infect. Dis.* **195**, 1018–1028 (2007).
108. Murray, C. S. *et al.* Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. *Thorax* **61**, 376–382 (2006).
109. Green, R. M. *et al.* Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. *BMJ* **324**, 763 (2002).
110. Legg, J. P., Hussain, I. R., Warner, J. A., Johnston, S. L. & Warner, J. O. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. *Am. J. Respir. Crit. Care Med.* **168**, 633–639 (2003).
111. Zhang, G. *et al.* Interleukin-10/interleukin-5 responses at birth predict risk for respiratory infections in children with atopic family history. *Am. J. Respir. Crit. Care Med.* **179**, 205–211 (2009).
112. Bont, L. *et al.* Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis. *Eur. Respir. J.* **14**, 144–149 (1999).
113. Forton, J. T. *et al.* Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. *Thorax* **64**, 345–352 (2009).
114. Mamessier, E. *et al.* T-cell activation during exacerbations: a longitudinal study in refractory asthma. *Allergy* **63**, 1202–1210 (2008).
115. Monick, M. M. *et al.* Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. *J. Immunol.* **179**, 1648–1658 (2007).
116. Chen, H. *et al.* Activation of STAT6 by STING is critical for antiviral innate immunity. *Cell* **147**, 436–446 (2011).
117. Allakhverdi, Z. *et al.* Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potentially activates mast cells. *J. Exp. Med.* **204**, 253–258 (2007).
118. Qiao, J., Li, A. & Jin, X. TSLP from RSV-stimulated rat airway epithelial cells activates myeloid dendritic cells. *Immunol. Cell Biol.* **89**, 231–238 (2010).
119. Kato, A., Favoreto, S. Jr., Avila, P. C. & Schleimer, R. P. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. *J. Immunol.* **179**, 1080–1087 (2007).
120. Uller, L. *et al.* Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon- β in bronchial epithelial cells from donors with asthma. *Thorax* **65**, 626–632 (2010).
121. Kaiko, G. E., Phipps, S., Angkasekwinai, P., Dong, C. & Foster, P. S. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. *J. Immunol.* **185**, 4681–4690 (2010).
This study demonstrates the important role of natural killer cell-derived IFN γ in controlling IL-25 production during human RSV infection. This study highlights the potential for viruses to elicit Th $_2$ type immune responses in the absence of IFN γ .
122. Welliver, R. C. *et al.* The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. *N. Engl. J. Med.* **305**, 841–846 (1981).
123. Dakhama, A. *et al.* The role of virus-specific immunoglobulin E in airway hyperresponsiveness. *Am. J. Respir. Crit. Care Med.* **170**, 952–959 (2004).
124. Dakhama, A. *et al.* Virus-specific IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice. *J. Allergy Clin. Immunol.* **123**, 138–145.e5 (2009).
125. Grayson, M. H. *et al.* Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. *J. Exp. Med.* **204**, 2759–2769 (2007).
126. Corne, J. M. *et al.* Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. *Lancet* **359**, 831–834 (2002).
127. Wark, P. A. *et al.* Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J. Exp. Med.* **201**, 937–947 (2005).
128. Contoli, M. *et al.* Role of deficient type III interferon- λ production in asthma exacerbations. *Nature Med.* **12**, 1023–1026 (2006).
This investigation shows the important protective role of IFN λ proteins in asthma exacerbations and that patients with asthma have impaired IFN λ expression and protein production.
129. Bochkov, Y. A. *et al.* Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. *Mucosal Immunol.* **3**, 69–80 (2010).
130. Lopez-Souza, N. *et al.* *In vitro* susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. *J. Allergy Clin. Immunol.* **123**, 1384–1390.e2 (2009).
131. Kormann, M. S. *et al.* Toll-like receptor heterodimer variants protect from childhood asthma. *J. Allergy Clin. Immunol.* **122**, 86–92.e8 (2008).
132. Schedel, M. *et al.* IRF-1 gene variations influence IgE regulation and atopy. *Am. J. Respir. Crit. Care Med.* **177**, 613–621 (2008).
133. Carvalho, A. *et al.* Polymorphisms in Toll-like receptor genes and susceptibility to pulmonary aspergillosis. *J. Infect. Dis.* **197**, 618–621 (2008).
134. Papadopoulos, N. G. *et al.* Viruses and bacteria in acute asthma exacerbations – a GA 2 LEN-DARE systematic review. *Allergy* **66**, 458–468 (2010).
135. Woodruff, P. G. *et al.* T helper type 2-driven inflammation defines major sub-phenotypes of asthma. *Am. J. Respir. Crit. Care Med.* **180**, 388–395 (2009).
136. Corren, J. *et al.* Lebrikizumab treatment in adults with asthma. *N. Engl. J. Med.* **365**, 1088–1098 (2011).
137. Borish, L. C. *et al.* Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. *Am. J. Respir. Crit. Care Med.* **160**, 1816–1823 (1999).
138. Leckie, M. J. *et al.* Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* **356**, 2144–2148 (2000).
139. Busse, W. W. *et al.* Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N. Engl. J. Med.* **364**, 1005–1015 (2011).
140. Morjaria, J. B. *et al.* The role of a soluble TNF α receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. *Thorax* **63**, 584–591 (2008).

141. Brehm, J. M. *et al.* Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. *J. Allergy Clin. Immunol.* **126**, 52–58.e5 (2010).
142. Urashima, M. *et al.* Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am. J. Clin. Nutr.* **91**, 1255–1260 (2009).
143. Xystrakis, E. *et al.* Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. *J. Clin. Invest.* **116**, 146–155 (2006).
144. Kalliomaki, M. *et al.* Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet* **357**, 1076–1079 (2001).
145. Chen, Y. S., Jan, R. L., Lin, Y. L., Chen, H. H. & Wang, J. Y. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. *Pediatr. Pulmonol* **45**, 1111–1120 (2010).
146. Yoo, J., Tcheurekdjian, H., Lynch, S. V., Cabana, M. & Boushey, H. A. Microbial manipulation of immune function for asthma prevention: inferences from clinical trials. *Proc. Am. Thorac. Soc.* **4**, 277–282 (2007).
147. Van, L. P. *et al.* Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms. *Eur. J. Immunol.* **41**, 1992–1999 (2011).
148. Xirakia, C. *et al.* Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. *Am. J. Respir. Crit. Care Med.* **181**, 1207–1216 (2010).
149. Simon, H. U., Seelbach, H., Ehmann, R. & Schmitz, M. Clinical and immunological effects of low-dose IFN- α treatment in patients with corticosteroid-resistant asthma. *Allergy* **58**, 1250–1255 (2003).
150. Koltzida, O. *et al.* IL-28A (IFN- λ 2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. *EMBO Mol. Med.* **3**, 348–361 (2011).

Acknowledgements

The authors were supported by the Comprehensive Biomedical Research Centre (cBRC) of Imperial College London, UK. M.R.E. was supported by an Asthma UK Fellowship (RF-07_04), S.L.J. received UK Medical Research Council (MRC) project grant G0601236 and European Research Council FP7 Advanced grant 233015, and M.R.E. and S.L.J. were jointly supported by the Asthma UK Clinical Chair (CH1155) and MRC Centre grant G1000758. P.O. is supported by Wellcome Trust strategic and programme grants (090382/Z/09/Z and 083567/Z/07/Z) and the MRC.

Competing interests statement

The authors declare no competing financial interests.